CARDIFF ONCOLOGY, INC. Cost of Revenue
CARDIFF ONCOLOGY, INC. (CRDF) reported Cost of Revenue of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Expense Statement
us-gaap:CostOfRevenue · last filed 2020-02-27
- CARDIFF ONCOLOGY, INC. cost of revenue for the quarter ending 2019-12-31 was $0.00.
- CARDIFF ONCOLOGY, INC. cost of revenue for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. cost of revenue for the quarter ending 2019-06-30 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. cost of revenue for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- CARDIFF ONCOLOGY, INC. cost of revenue for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- CARDIFF ONCOLOGY, INC. cost of revenue for fiscal 2018 was $597.46K, a 67.02% decline from fiscal 2017.
- CARDIFF ONCOLOGY, INC. cost of revenue for fiscal 2017 was $1.81M, a 4.68% increase from fiscal 2016.
- CARDIFF ONCOLOGY, INC. cost of revenue for fiscal 2016 was $1.73M, a 175.04% increase from fiscal 2015.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $0.00 derived: sum of 3 quarters · filed 2020-02-27 | $0.00 10-K · filed 2020-02-27 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $0.00 10-Q · filed 2019-11-07 | $0.00 derived: sum of 4 quarters · filed 2020-02-27 |
| 2019-06-30 | $0.00 10-Q · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | $0.00 derived: sum of 3 quarters · filed 2020-02-27 | $26.68K derived: sum of 4 quarters · filed 2020-02-27 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-07 | $0.00 derived: sum of 2 quarters · filed 2020-02-27 | $26.68K derived: sum of 3 quarters · filed 2020-02-27 | $231.11K derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $26.68K derived: sum of 2 quarters · filed 2020-02-27 | $231.11K derived: sum of 3 quarters · filed 2020-02-27 | $597.46K 10-K · filed 2020-02-27 |
| 2018-09-30 | $26.68K 10-Q · filed 2019-11-07 | $231.11K derived: sum of 2 quarters · filed 2019-11-07 | $597.46K 10-Q · filed 2019-11-07 | $981.05K derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $204.44K 10-Q · filed 2019-08-08 | $570.78K 10-Q · filed 2019-08-08 | $954.37K derived: sum of 3 quarters · filed 2019-08-08 | $1.43M derived: sum of 4 quarters · filed 2019-08-08 |
| 2018-03-31 | $366.34K 10-Q · filed 2019-05-07 | $749.94K derived: sum of 2 quarters · filed 2019-05-07 | $1.22M derived: sum of 3 quarters · filed 2019-05-07 | $1.56M derived: sum of 4 quarters · filed 2019-05-07 |
| 2017-12-31 | $383.59K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $856.79K derived: sum of 2 quarters · filed 2019-03-06 | $1.19M derived: sum of 3 quarters · filed 2019-03-06 | $1.81M 10-K · filed 2019-03-06 |
| 2017-09-30 | $473.20K 10-Q · filed 2018-11-07 | $811.40K derived: sum of 2 quarters · filed 2018-11-07 | $1.43M 10-Q · filed 2018-11-07 | $2.02M derived: sum of 4 quarters · filed 2018-11-07 |
| 2017-06-30 | $338.20K 10-Q · filed 2018-08-03 | $954.63K 10-Q · filed 2018-08-03 | $1.54M derived: sum of 3 quarters · filed 2018-08-03 | $1.97M derived: sum of 4 quarters · filed 2018-08-03 |
| 2017-03-31 | $616.43K 10-Q · filed 2018-05-08 | $1.20M derived: sum of 2 quarters · filed 2018-05-08 | $1.63M derived: sum of 3 quarters · filed 2018-05-08 | $2.04M derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | $587.22K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $1.01M derived: sum of 2 quarters · filed 2018-02-26 | $1.42M derived: sum of 3 quarters · filed 2018-02-26 | $1.73M 10-K · filed 2018-02-26 |
| 2016-09-30 | $424.56K 10-Q · filed 2017-11-09 | $834.02K derived: sum of 2 quarters · filed 2017-11-09 | $1.14M 10-Q · filed 2017-11-09 | $1.34M derived: sum of 4 quarters · filed 2017-11-09 |
| 2016-06-30 | $409.46K 10-Q · filed 2017-08-09 | $718.73K 10-Q · filed 2017-08-09 | $917.93K derived: sum of 3 quarters · filed 2017-08-09 | $1.09M derived: sum of 4 quarters · filed 2017-08-09 |
| 2016-03-31 | $309.27K 10-Q · filed 2017-05-10 | $508.47K derived: sum of 2 quarters · filed 2017-05-10 | $682.01K derived: sum of 3 quarters · filed 2017-05-10 | $762.04K derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-31 | $199.20K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $372.74K derived: sum of 2 quarters · filed 2017-03-15 | $452.77K derived: sum of 3 quarters · filed 2017-03-15 | $629.19K 10-K · filed 2017-03-15 |
| 2015-09-30 | $173.54K 10-Q · filed 2016-11-09 | $253.57K derived: sum of 2 quarters · filed 2016-11-09 | $429.99K 10-Q · filed 2016-11-09 | $445.43K derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | $80.03K 10-Q · filed 2016-08-04 | $256.45K 10-Q · filed 2016-08-04 | $271.90K derived: sum of 3 quarters · filed 2017-03-15 | $271.90K derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-03-31 | $176.43K 10-Q · filed 2016-05-10 | $191.87K derived: sum of 2 quarters · filed 2017-03-15 | $191.87K derived: sum of 3 quarters · filed 2017-03-15 | |
| 2014-12-31 | $15.44K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $15.44K derived: sum of 2 quarters · filed 2017-03-15 | $15.44K 10-K · filed 2017-03-15 | |
| 2014-09-30 | $0.00 10-Q · filed 2015-11-09 | $0.00 10-Q · filed 2015-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |